Add this topic to your myFT Digest for news straight to your inbox
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
Analysts hope artificial intelligence can reveal what is not said on earnings calls
Rare step comes after Brussels fined US biotech for buying Grail without approval
Illumina-owned cancer testing group allegedly failed to deal with accusations of inappropriate behaviour and racism
US gene sequencing company proceeded with acquisition of cancer test developer even as regulators were probing deal
World’s biggest gene sequencing group closed deal with cancer screening start-up despite ongoing investigation
Antitrust challenge may force big pharma groups to rethink ‘pure play’ business models
Error prompts life assurance customers to pause or review relationship with early detection biotech
World’s biggest gene sequencing company rejects EU’s fast- track application
Investors are pouring billions into companies claiming they can analyse DNA to find the disease early. But some scientists question if they really work
Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail
Founding directors say political wrangling causing delays to potentially life-saving blood test
FTC warns acquisition would hurt competition in the market for early detection cancer tests
Activist investor steps up battle over ‘disastrous’ acquisition by world’s biggest genome sequencer
Comments by activist investor come ahead of US central bank’s rate-setting meeting next week
Company’s shares jump after activist investor launches proxy battle
Ruling allows European probe of Illumina’s $8bn Grail takeover and sets precedent for deeper oversight of deals
US biotech takes aggressive step over cancer-screening deal fearing Brussels review will not beat deadline
International Edition